scorecard
  1. Home
  2. Science
  3. Health
  4. news
  5. The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug

The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug

Lydia Ramsey Pflanzer   

The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug

Hello,

Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...



Here are the 9 biggest biotech winners after the FDA took an entirely new approach to approve Biogen's Alzheimer's drug

  • A historic approval of Biogen's Alzheimer's drug will have ramifications across the drug industry.
  • Analysts expect Aduhelm's launch to spur more investor interest in Alzheimer's research.

Here are the nine companies that stand to benefit the most>>


Why General Atlantic's top healthcare dealmaker is betting on telemedicine sticking around long after the pandemic subsides

Read more from the interview here>>


Clover Health gained more than 80% as WallStreetBets fueled the meme-stock rally

Here's what happened>>


More stories we're reading:


- Lydia

READ MORE ARTICLES ON



Popular Right Now



Advertisement